Grantham Mayo Van Otterloo & Co. LLC Acquires 23,853 Shares of Humana Inc. (NYSE:HUM)

Grantham Mayo Van Otterloo & Co. LLC grew its holdings in shares of Humana Inc. (NYSE:HUM - Free Report) by 144.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 40,365 shares of the insurance provider's stock after buying an additional 23,853 shares during the period. Grantham Mayo Van Otterloo & Co. LLC's holdings in Humana were worth $10,241,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the stock. HighTower Advisors LLC grew its holdings in Humana by 2.1% in the third quarter. HighTower Advisors LLC now owns 8,992 shares of the insurance provider's stock worth $2,852,000 after purchasing an additional 187 shares during the period. IHT Wealth Management LLC grew its stake in shares of Humana by 38.2% in the 3rd quarter. IHT Wealth Management LLC now owns 1,082 shares of the insurance provider's stock valued at $334,000 after buying an additional 299 shares during the period. Quarry LP increased its position in Humana by 862.9% in the 3rd quarter. Quarry LP now owns 337 shares of the insurance provider's stock valued at $107,000 after buying an additional 302 shares in the last quarter. Stifel Financial Corp raised its stake in Humana by 8.8% during the 3rd quarter. Stifel Financial Corp now owns 59,432 shares of the insurance provider's stock worth $18,825,000 after buying an additional 4,804 shares during the period. Finally, Kovitz Investment Group Partners LLC boosted its holdings in Humana by 61.6% in the third quarter. Kovitz Investment Group Partners LLC now owns 4,179 shares of the insurance provider's stock worth $1,324,000 after acquiring an additional 1,593 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company's stock.

Remove Ads

Humana Stock Performance

Shares of HUM stock traded up $1.98 during trading hours on Friday, hitting $292.23. 585,142 shares of the company were exchanged, compared to its average volume of 1,743,884. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. The stock has a market capitalization of $35.27 billion, a price-to-earnings ratio of 29.34, a P/E/G ratio of 2.05 and a beta of 0.62. The firm has a fifty day simple moving average of $265.56 and a 200 day simple moving average of $270.77. Humana Inc. has a 52-week low of $213.31 and a 52-week high of $406.46.

Humana (NYSE:HUM - Get Free Report) last released its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Research analysts predict that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be given a dividend of $0.885 per share. The ex-dividend date is Friday, March 28th. This represents a $3.54 annualized dividend and a yield of 1.21%. Humana's payout ratio is presently 35.58%.

Analyst Ratings Changes

Several research firms have recently commented on HUM. Morgan Stanley decreased their price objective on Humana from $301.00 to $285.00 and set an "equal weight" rating for the company in a report on Wednesday, February 12th. StockNews.com upgraded shares of Humana from a "hold" rating to a "buy" rating in a research note on Monday. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $283.00 price objective on shares of Humana in a research note on Wednesday, February 12th. Mizuho boosted their target price on shares of Humana from $305.00 to $316.00 and gave the stock an "outperform" rating in a research report on Wednesday. Finally, JPMorgan Chase & Co. lowered their target price on shares of Humana from $257.00 to $256.00 and set a "neutral" rating on the stock in a report on Tuesday, February 18th. Seventeen research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Humana currently has a consensus rating of "Hold" and an average price target of $286.00.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.